BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
InnoCare Pharma Ltd. (9969.HK; 688428.SH) said on Thursday its revenue rose 37% last year to 1.01 billion yuan ($138 million), fueled by strong gains for Orelabrutinib, its drug used to…
9969.HK
688428.SHG
Recent Articles
BRIEF: InnoCare revenue jumps 37% in 2024 on strong lymphoma drug sales
9969.HK
688428.SHG
RECENT ARTICLES
-
BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium
9969.HK 688428.SHG
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
DPC Dash serves up banner 2024 topped with milestones
1405.HK
-
Horizon’s lead grows in smart driving race with new product rollouts
9660.HK
-
Dingdong rings up strong end to 2024, but warns of turbulence ahead
DDL.US
-
After profit plunge in 2024, Maoyan spotlights strong start to 2025
1896.HK
Discover hidden China stock gems in our weekly newsletter